Garfield G. Duncan, M.D., F.A.C.P.; Frank A. Elliott, M.D.; Theodore G. Duncan, M.D., F.A.C.P.; Joseph Schatanoff, M.D.
This content is PDF only. Please click on the PDF icon to access.
Preliminary clinical observations of clofibrate A therapy in 24 patients—obese and nonobese, diabetic and nondiabetic—exhibiting hypercholesterolemia with and without an associated hypertriglyceridemia and blood sludging in conjunctival vessels have shown with remarkable consistency a precipitous reduction in both serum cholesterol and triglycerides, a marked amelioration of blood sludging in the conjunctival vessels, reduced stickiness of the blood platelets, subsiding evidences of coronary insufficiency in five successive patients, subjective improvement in intractable cases of diabetic neuropathy, and a prompt reversal of the hyperlipidemia upon withdrawal of the clofibrate.
No unfavorable effects on diabetes nor other untoward manifestations have been detected. This
Duncan GG, Elliott FA, Duncan TG, et al. Clinical Potential of Chlorophenoxyisobutyrate (CPIB: Clofibrate) in the Management of Hypercholesterolemia—A Preliminary Report.. Ann Intern Med. 1967;66:1058. doi: https://doi.org/10.7326/0003-4819-66-5-1058_1
Download citation file:
Published: Ann Intern Med. 1967;66(5):1058.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use